C16 Glucosylceramide-d3 (d18:1/16:0-d3)
|
- $535
- Product name: C16 Glucosylceramide-d3 (d18:1/16:0-d3)
- CAS:
- MF: C40H74D3NO8
- MW: 703.059765334
- EINECS:
- MDL Number:
- Synonyms:C16 Glucosylceramide-d3 (d18:1/16:0-d3)
1 prices
Selected condition：
Brand
- Cayman Chemical
Package
- 1mg
- ManufacturerCayman Chemical
- Product number24621
- Product descriptionC16 Glucosylceramide-d3 (d18:1/16:0-d3) ≥99%deuteratedforms(d1-d3)
- Packaging1mg
- Price$535
- Updated2026-04-30
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Cayman Chemical | 24621 | C16 Glucosylceramide-d3 (d18:1/16:0-d3) ≥99%deuteratedforms(d1-d3) | 1mg | $535 | 2026-04-30 | Buy |
Properties
solubility :Chloroform:
Methanol: (2:1): Soluble
Methanol: (2:1): Soluble
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|
Description
C16 Glucosylceramide-d3 is intended for use as an internal standard for the quantification of C16 glucosylceramide by GC- or LC-MS. C16 glucosylceramide is an endogenous bioactive sphingolipid.1,2 It is a precursor in the synthesis of C16 lactosylceramide (Item No. 24352) that is formed via metabolism of C16 ceramide (Item No. 10681) by glucosylceramide synthase.3 Inhalation of C16 glucosylceramide reduces lung colonization by P. aeruginosa and increases survival in a mouse model of cystic fibrosis.1 C16 Glucosylceramide levels are elevated in the plasma of Parkinson's disease patients with cognitive impairments.2 As this product is derived from a natural source, there may be variations in the sphingoid backbone. [Matreya, LLC. Catalog No. 1533]WARNING This product is not for human or veterinary use.More related product prices